Clinical applications of hallucinogens: a review

Garcia-Romeu, Albert, Kersgaard, Brennan, Addy, Peter H.·2016·Experimental and Clinical Psychopharmacology
DOI 10.1037/pha0000084

Cited by (201)

Items 101–200 of 201

  1. The therapeutic potential of psychedelic substances in Hospice and Palliative Care
    Ana Cláudia Mesquita Garcia, Lucas Oliveira Maia · 2022 · Progress in Palliative Care
  2. The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders
    Vivian Kim, Scott Maxwell Wilson, Mary E. Woesner · 2024 · Journal of Clinical Psychopharmacology
  3. Aggressive behaviours associated with MDMA and psychedelics: a narrative review
    Negar Sayrafizadeh, Nicole Ledwos, Muhammad Ishrat Husain, David Jonathan Castle · 2024 · Acta Neuropsychiatrica
  4. The phenomenology of psychedelic temporality: current knowledge, open questions, and clinical applications
    Riccardo Miceli McMillan, Jack Reynolds, Anthony Vincent Fernandez · 2024 · Philosophical Psychology
  5. Impact of psychedelics on craving in addiction: A systematic review
    Sophie‐Athéna Chapron, Guilhem Bonazzi, Laura Di Lodovico, Julia de Ternay, Camille Landmann, Mikaïl Nourredine, Francesco Salvo, Ben Sessa, Ravi Das, Benjamin Rolland et al. · 2025 · Journal of Psychopharmacology
  6. A Nationwide Study Comparing Mental Health Professionals’ Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice
    Yotam David Ginati, Nir Madjar, Joseph Ben-Sheetrit, Shaul Lev‐Ran, Abraham Weizman, Gal Shoval · 2021 · Journal of Psychoactive Drugs
  7. Antidepressants
    Richard A. Glennon, Leslie Lars Iversen · 2021 · Wiley eBooks
  8. Continuous flow synthesis of N , N -dimethyltryptamine (DMT) analogues with therapeutic potential
    Andreas Simoens, Andreas Dejaegere, Marthe Vandevelde, Christian Victor Stevens · 2024 · RSC Medicinal Chemistry
  9. Structural and Functional Aspects of Muscarinic Receptors in Correlation with Anticholinergic Drugs
    Pramod Kumar Singh, Rajendra Nath, Ram Naraian, Manish Kumar Gupta · 2020 · Springer eBooks
  10. Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care
    Sivan Schipper, Kabir B. Nigam, Vanessa Piechotta, Michael Ljuslin, Yvan Beaussant, Guido Schwarzer, Christopher S. Boehlke · 2022 · Cochrane Database of Systematic Reviews
  11. Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics
    Kelan L. H. Thomas, Robert Jesse, Nicky J. Mehtani, Jennifer Mitchell, Brian T. Anderson · 2023 · Journal of Psychoactive Drugs
  12. Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights
    Isabella Henderson, Ronnie Elsaadany, Gabriel Chan, Vikram Bajaj, Diana Duarte, Sadie Goodman, Michael Grunstein, Nehal P. Vadhan, Robert Duarte · 2025 · Current Pain and Headache Reports
  13. Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress
    Noah D. Gold, Samantha K. Podrebarac, Lindsay A. White, Christina Marini, Naomi M. Simon, Mary Sherman Mittelman, Stephen Ross, Michael P. Bogenschutz, Petros D. Petridis · 2023 · Psychedelic Medicine
  14. Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex
    Victorita E. Ivan, David P. Tomàs‐Cuesta, Ingrid M. Esteves, Artur Luczak, Majid H. Mohajerani, Bruce L. McNaughton, Aaron J. Gruber · 2024 · European Journal of Neuroscience
  15. Adverse Effects and Safety of Antidepressants and Psychedelics for Depression in Cancer: A Systematic Review of Randomized Controlled Trials
    Renan Massanobu Maekawa, Lorena Terene Lopes Guerra, José Carlos Bouso, Jaime E. C. Hallak, RAFAEL GUIMARÃES DOS SANTOS · 2025 · Psychoactives
  16. Ayahuasca
    Deana Shevit Goldin, Deborah A. Salani · 2021 · Journal of Addictions Nursing
  17. New Approach in Prevention of Shivering with Spinal Anesthesia
    EhabE Afifi, Marwa Maged Abouseeda, Taghreed Mohamed · 2023 · Benha Journal of Applied Sciences
  18. Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
    Daniel J. Kruger, Jeff Albrecht, Jacob S. Aday, Julie Barron, Moss Herberholz, Kevin F. Boehnke · 2025 · Journal of Psychoactive Drugs
  19. Evaluation of phenylethylamine type entactogens and their metabolites relevant to ecotoxicology – a QSAR study
    Milena Jadrijević-Mladar Takač, Joao Magina, Tin Takač · 2019 · Acta Pharmaceutica
  20. Neuropsychological Assessment of Learning and Memory in Rats Following Ketamine Exposure during Late Adolescence
    Julianna M. Davis, David M. Compton, Miranda Heit, Ashley Fravel, Kimberly Wood · 2020 · Journal of Behavioral and Brain Science
  21. New psychoactive substances in Poland: an overview of psychodysleptics (lysergamides and tryptamines)
    Gabriel Słonina, K. Janczura · 2018 · World Scientific News
  22. État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle
    Christian Sueur · 2018 · Psychotropes
  23. Examining the influence of team-based learning on medical students’ comprehension and attitudes regarding psychedelic therapies
    Shiven Chaudhry, Anne Weisman, Molly M. Hagen, Kathryn L. S. Pauli, Burton Jared Tabaac · 2024 · Dialogues in Clinical Neuroscience
  24. Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
    Michael Davidson, Gabriela Dumitriţa Stanciu, Jonathan Rabinowitz, Ilinca Untu, Romeo Dobrin, Bogdan-Ionel Tamba · 2025 · Dialogues in Clinical Neuroscience
  25. Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
    Niloufar Pouyan, Jacob S. Aday, Steven E. Harte, Chelsea M. Kaplan, David A. Williams, Nicolas G. Glynos, Moss Herberholz, Daniel J. Kruger, Julie Barron, George A. Mashour et al. · 2025 · Journal of Psychopharmacology
  26. Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?
    Albert Garcia‐Romeu · 2025 · NPP—Digital Psychiatry and Neuroscience
  27. A scoping review of variations in psychedelic interventions for psychological suffering associated with the end of life
    Sarah Kratina, Carol Strıke, Robert D. Schwartz, Ayah Nayfeh, Sydney A. Jopling, Christopher Lo, Brian R. Rush · 2025 · Social Science & Medicine
  28. Psychoactive plants and phytochemicals
    Mohamed A. Salem, Ahmed Zayed, Shahira M. Ezzat · 2021 · Elsevier eBooks
  29. The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer’s Disease
    Martin I. Steinberg, Paul Rosenberg, Albert Garcia‐Romeu · 2023 · Current Geriatrics Reports
  30. Stimulant Drugs: Introduction
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  31. Articulation de la thérapie d’acceptation et d’engagement à la psychothérapie assistée par psychédéliques en addictologie
    Lana Strika-Bruneau, Baptiste Fauvel, David Dupuis, Amine Benyamina · 2023 · L Évolution Psychiatrique
  32. A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life
    Sarah Kratina, Carol Strıke, Robert D. Schwartz, Ayah Nayfeh, Sydney A. Jopling, Christopher Lo, Brian R. Rush · 2025 · PLoS ONE
  33. Analytical detection of New Psychoactive Substances in biological samples: a Systematic Review
    Michele Goulart dos Santos, Vinicius Vescovi, Ruthinéia Jéssica Alves do Nascimento · 2025 · Revista Brasileira de Criminalística
  34. The effects of psychedelics on neuroplasticity: A review of current research and the possibility of therapeutic application in psychiatry
    Mile Jevtić · 2025 · Engrami
  35. Impact of substance abuse on polycystic ovarian syndrome
    L. Ajayi, M. C. Onaolapo, G. Akanbi, A. H. Ayodele, M. Alabi, Grace Oluwatomiwa Gbenga, O. Akano, Ayodeji Folorunsho Ajayi · 2025 · Discover Endocrinology and Metabolism
  36. Psychedelics for the Treatment of Substance Use Disorders
    Johannes Klaus, Fritz Schneider, Rena Schaletzky, Daniel Sippel, Anil Batra · 2025 · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice
  37. Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis
    Maite Armanino-Irigaray, Ana Catalán, Clàudia Aymerich, Borja Pedruzo, Ignacio Argüelles, Alazne Ramírez, Eleonora Armyra, Miguel Angel Gonzalez-Torres, Gonzalo Salazar de Pablo · 2026 · Child and Adolescent Psychiatry and Mental Health
  38. From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care
    Joshua Mitchell, Logan Neitzke‐Spruill, David S. Mathai, Jill Oliver Robinson, Zuzana Kazan, Lynnette A. Averill, Amy L. McGuire · 2026 · Translational Behavioral Medicine
  39. Plantes psychotropes, médecines traditionnelles autochtones du Pérou et renaissance psychédélique
    IIana Berlowitz · 2022 · Drogues santé et société
  40. Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future
    Anna C. Douglas, Daniel J. Staas, Anna Hampton, Kylie Burns, Fenn Suter · 2023 · Georgetown Scientific Research Journal
  41. Perioperative considerations for patients exposed to hallucinogens
    Trent D. Emerick, Tetyana Marshall, Thomas Jeff Martin, Doug Ririe · 2024 · Regional Anesthesia & Pain Medicine
  42. More Than “Somnambulism”
    Etzel Cardeña · 2024 · Oxford University Press eBooks
  43. Ibogaine: History, Pharmacology, Spirituality, & Clinical Data
    Benjamin Shapiro · 2018
  44. Intercultural, intermolecular: An ethnobotanical examination of the potential therapeutic value of LSD for the treatment of depression
    Karsten Fatur · 2019 · Journal of Psychedelic Studies
  45. Tracking brain dynamics across transitions of consciousness
    Iulia M. Comșa · 2018 · Apollo (University of Cambridge)
  46. Psilocybin reduces functional connectivity and the encoding of spatial information by neurons in mouse retrosplenial cortex
    Victorita E. Ivan, David P. Tomàs‐Cuesta, Ingrid M. Esteves, Artur Luczak, Majid H. Mohajerani, Bruce L. McNaughton, Aaron J. Gruber · 2024
  47. Introduction to the special issue: 50th anniversary of APA Division 28: The past, present, and future of psychopharmacology and substance abuse.
    William Walton Stoops, Stacey C. Sigmon, Suzette M. Evans · 2016 · Experimental and Clinical Psychopharmacology
  48. Transforming The Fear Of Death Through Near-Death Experiences And Experiential Psychedelics: A Transpersonal Hermeneutic Phenomenological Inquiry
    Janet Nielsen · 2019
  49. Club Drugs and Novel Psychoactive Substances
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  50. A Brief History of NPS Production and Distribution
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  51. Stimulant Drugs: Synthetic Cathinones
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  52. Stimulant Drugs: Methamphetamine
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  53. Classification Framework for Club Drugs and NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  54. Stimulant Drugs: Amphetamine-Type Stimulants
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  55. Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  56. The Clinical Challenge of Club Drugs and NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  57. Depressant Drugs: Benzodiazepine NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  58. L’Appel de la forêt : étude exploratoire des trajectoires des néo-usagers d’ayahuasca
    B. Beslon, Vincent Wagner, Didier Acier · 2021 · Annales Médico-psychologiques revue psychiatrique
  59. Stimulant Drugs: Cocaine
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  60. Synthetic Cannabinoid Receptor Agonists (SCRAs)
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  61. Stimulant Drugs: MDMA and Drugs with Similar Effects
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  62. What Are Club Drugs and NPS and Why Are They Important?
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  63. A VIVÊNCIA DA SEXUALIDADE NOS IDOSOS: UMA LEITURA HOLÍSTICA ATRAVÉS DA ENFERMAGEM
    Rogério de Moraes Franco Júnior, Thays Peres Brandão, Acleverson José dos Santos · 2021 · Editora Omnis Scietia eBooks
  64. Avaliação das possíveis interações entre o canabidiol e a ayahuasca em voluntários saudáveis: um estudo randomizado, duplo-cego e controlado com placebo
    Giordano Novak Rossi · 2020
  65. CAPACITAÇÕES DOS PROFISSIONAIS DE SAÚDE SOBRE NOTIFICAÇÃO DAS ARBOVIROSES NA PANDEMIA POR COVID-19 EM RECIFE
    Ana Cláudia da Silva Santiago, Maria Luiza Ferreira Imburana da Silva, Laiane Moreira Vianna Magalhães, Jurandir Alves de Almeida Júnior, Maísa Cavalcanti Pereira · 2021 · Editora Omnis Scietia eBooks
  66. ORGANIZAÇÃO DOS SISTEMAS E SERVIÇOS DE SAÚDE DO SUDOESTE BAIANO: UM OLHAR SOBRE GESTÃO EM SAÚDE NO CONTEXTO DA PANDEMIA COVID-19
    Ana Clara Carvalho Cardoso Brito, Ludimila Santos Muniz, Regina de Souza Moreira, Noemi Silva Pereira Costa, Neuranides Santana, Rafael Damasceno de Barros · 2021 · Editora Omnis Scietia eBooks
  67. DORES CRÔNICAS E USO DE ÁLCOOL, CANNABIS, ALUCINÓGENOS E OPIOIDES: PERSPECTIVAS NEUROBIOLÓGICAS E PSICOSSOCIAIS
    Richard Alecsander Reichert, Daniel A. Sales, Suyanne Kristini da Rosa Wisnieski, Rafaela da Silva Frizzo, Thaís Hoffmann Stump, Denise de MICHELI, Wanderlei Abadio de Oliveira, Felipe Anselmo Pereira, Rosana Fanucci Silva Ramos, Suzanna Araújo Preuhs et al. · 2021 · Editora Omnis Scietia eBooks
  68. Designer Drugs
    Neelambika Revadigar, Ching Tary Yu, Isabelle Silverstone-Simard · 2022 · Springer eBooks
  69. Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  70. Concluding Remarks
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  71. Depressant Drugs: Introduction
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  72. Depressant Drugs: Ketamine and Its Analogues
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  73. Introduction
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  74. Hallucinogens
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  75. Plausible Mechanism in Prevention/Reversal of Oral Psychosomatic Disorders vis-à-vis Endogenous Secretion of N, N-Dimethyltryptamine
    Khalil Ibrahim Assiri, Jagadish Hosmani, Abdullah Alqarni · 2022 · World Journal of Dentistry
  76. Index
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  77. Vibrational analysis of hallucinogenic amphetamines
    Iulia-Florentina Darie, Mirela Praisler · 2022 · Annals of the ”Dunarea de Jos” University of Galati Fascicle II Mathematics Physics Theoretical Mechanics
  78. A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues
    Sarah Kratina, Christopher Lo, Robert D. Schwartz, Carol Strıke, Sydney A. Jopling, Ayah Nayfeh, Brian R. Rush · 2023
  79. Exploring inner depths
    Joost J. Breeksema · 2024
  80. Efeitos do uso da Ayahuasca utilizada em Cerimônias religiosas sobre aspectos emocionais dos participantes
    Felipe Teixeira · 2024 · Revista Ouricuri
  81. From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine
    Nicholas A Kerna, Kevin D. Pruitt, N.D. Victor Carsrud, Kyle Kadivi, Dabeluchi Chiedozie Ngwu, Hilary M. Holets, John V. Flores, Ijeoma Nnake, Cornelius Ituma Azi, Joseph Anderson et al. · 2024 · European Journal of Arts Humanities and Social Sciences
  82. "Vine of the Soul": The Potential of Ayahuasca for Reducing Depression, Anxiety, and Stress among Ceremony Participants and the Role of Rumination
    Banan Ramarushton · 2024
  83. Psilocybin in the Management of Substance Use Disorders: A Summary of Current Evidence
    Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij M. Satodiya, Rashmi Shukla, Samer El Hayek · 2024 · Current Psychopharmacologye
  84. Psychédéliques et psychédélisme, tour d’horizon
    Linda Amrouche · 2024 · Actualités Pharmaceutiques
  85. Prevalence and Correlates of Psychedelic Use in Poland: A Study on a Representative Sample of Polish Adults
    Paweł Holas, Justyna Kamińska · 2024 · Research Square
  86. Ego dissolution in psychedelic experience
    Philip Gerrans · 2024
  87. The Future of Alcohol Use Disorder Treatment and Research
    A. Benjamin Srivastava, Jonathan M. Wai · 2024 · Psychiatry update
  88. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature
    Alejandra Pulido-Saavedra, Anna Borelli, Razi Kitaneh, Mohammad Alrafayia, Laya Jalilian Khave, Melissa Christine Funaro, Marc Nicholas Potenza, Gustavo A. Angarita · 2024 · Expert Opinion on Pharmacotherapy
  89. Les nouveaux produits de synthèse au cœur du trafic de stupéfiants mondial
    Linda Amrouche · 2025 · Actualités Pharmaceutiques
  90. Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review
    Ritika Jagdeep Shah, Ashish Sarangi · 2025 · Alcoholism Treatment Quarterly
  91. Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany
    Sebastian Sattler, Suzanne C. Wood, Margit Anne Petersen, Fiona Seiffert, Guido Mehlkop · 2025 · Scientific Reports
  92. Psychedelics and the Ontology of Work: A Qualitative Study of Career Transformation, Spiritual Embodiment, and Purpose-Driven Labour
    Jeffrey S. Overall · 2025 · Journal of Management Spirituality & Religion
  93. Impacts of Drug Abuse and Addiction and Effects of Pharmaceuticals Misuse: Review Article
    Hiba Hussein Fadil Mahdi, Ghassan Jasim Mohammed · 2025 · Journal of Biomedicine and Biochemistry
  94. Capacity Building Through Psychedelic-Assisted Therapy
    Logan Neitzke‐Spruill, Jarrett Robert Rose · 2026 · Psychiatric Clinics of North America
  95. From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders
    Pravesh Sharma, Jared Kendrick, Jennifer Schram, Samuel Stumo, Averi Garscia, Douglas B. Matthews · 2026 · Journal of Psychopharmacology
  96. The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
    Flavia Giaffone de Paiva Ferreira, João Ariel Bonar Fernandes, Renato Filev, Dartiu Xavier da Silveira, Thiago Marques Fidalgo · 2026 · Journal of Psychopharmacology
  97. Psychedelics and Reward Processing: Before and After the 1970 Controlled Substances Act
    Dylan J. Lifshitz, M. Farris Sawaya, Kevin Sean Murnane · 2026 · Psychedelic Medicine
  98. Transpersonal Psychotherapies
    Jenny Wade, Phyllis Alongi, Jacqueline Hermida · 2026
  99. Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.
    D. Świeczkowski, A. Kwaśny, W. J. Cubała · 2026 · Journal of Psychoactive Drugs
  100. Perceptions and experiences of psychedelic substance use: a qualitative thematic analysis of Polish-language Reddit posts
    Ewa Jankowska, Damian Świeczkowski · 2026 · Drugs Education Prevention and Policy